Efficacy and Tolerability of Hairgain® in Individuals with Hair Loss: A Placebo-Controlled, Double-Blind Study

This randomized, placebo-controlled, double-blind study was designed to investigate the efficacy and tolerability of a new agent for the treatment of hair loss, based on a marine protein, minerals and vitamins. Sixty subjects with hair loss of different aetiologies participated in the 6-month blinded phase of the study. Objective assessments indicated that the treatment was effective and subjective assessments showed a statistically significant positive effect of treatment. Exposure to the active preparation for a further 6 months in an open phase indicated a further improvement in hair growth. Exposure of the patients previously treated with placebo to the active preparation for 12 months gave similar results. Tolerability was good and no side-effects were reported. The product investigated may provide an alternative to pharmacotherapy for the treatment of hair-loss problems in individuals with androgenic alopecia.

[1]  J. Barth.  Should men still go bald gracefully? , 2000, The Lancet.

[2]  Cash.  The psychosocial consequences of androgenetic alopecia: a review of the research literature , 1999, The British journal of dermatology.

[3]  M. Lebwohl,et al.  Finasteride in the treatment of men with frontal male pattern hair loss. , 1999, Journal of the American Academy of Dermatology.

[4]  J. Shapiro,et al.  Finasteride in the treatment of men with androgenetic alopecia. Finasteride Male Pattern Hair Loss Study Group. , 1998, Journal of the American Academy of Dermatology.

[5]  C. Mork.  [Hair loss. Causes, diagnosis, clinical manifestations and treatment]. , 1997, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke.

[6]  E. DeLong,et al.  Five-year follow-up of men with androgenetic alopecia treated with topical minoxidil. , 1990, Journal of the American Academy of Dermatology.